NCT02502097View on ClinicalTrials.gov

A Study of Gefapixant (AF-219/MK-7264) in Participants With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

August 26, 2015

Primary Completion Date

July 1, 2016

Study Completion Date

July 14, 2016

Conditions
Idiopathic Pulmonary FibrosisCough
Interventions
DRUG

Gefapixant

Gefapixant 50 mg tablet, administered by mouth

OTHER

Placebo

Matching placebo to gefapixant, tablet administered by mouth

All Listed Sponsors
lead

Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT02502097 - A Study of Gefapixant (AF-219/MK-7264) in Participants With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016) | Biotech Hunter | Biotech Hunter